Developing new drugs is a notoriously difficult and inefficient process, with only around 1 out of 20 drugs that show promise in animal testing will ultimately obtain regulatory approval for clinical applications. What are the reasons that drive this high attrition rate?
In PD Dr. Benhamin Ineichen's presentation, he will explore these reasons and discuss how he aims to contribute to a more rigorous drug development process using systematic review methodology and large language models to map the drug development process on a large scale.
